Galecto Inc.
Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation and cancer.
Galecto was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom and Denmark. The company is currently incorporated in the U.S. and headquartered in Copenhagen, Denmark.
See other Therapeutics organisations
-
AKL Research & Development Ltd.'s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system. -
Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. ... -
To 2014 - Antikor Biopharma Limited was established in mid-2014 following the restructuring of PhotoBiotics Limited. The new Company retains ... -
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science
Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.
Learn moreCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.